Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) | PAR 21 057

Opportunity Information: Apply for PAR 21 057

This funding opportunity, titled "Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)" (PAR-21-057), is a National Institutes of Health (NIH) program designed to push promising neurological or neuromuscular biomarkers past the early discovery stage and into a level of measurement rigor that supports real-world clinical and regulatory use. The central focus is not on finding new biomarkers, but on proving that a biomarker that already looks strong can be measured reliably, accurately, and reproducibly using an analytically validated method. The overarching goal is to make biomarker measurements consistent with expectations aligned to FDA-style analytical performance standards, so that later clinical validation or qualification steps can be built on trustworthy assay performance.

The announcement targets situations where the field is often most vulnerable: a candidate biomarker may be compelling biologically, and an assay platform may already exist, but the measurement procedure may not yet be locked down well enough to support multi-site studies, longitudinal tracking, or decision-making in clinical research and eventual clinical practice. This program therefore emphasizes rigorous evaluation and optimization of the analytical method itself. That includes studying the detection approach, establishing performance characteristics, and identifying the operating conditions that produce reproducible and accurate biomarker measurements. In practical terms, projects responsive to this announcement are expected to generate high-quality analytical validation evidence, such as how the assay performs across runs, operators, instruments, reagent lots, or sites, and what conditions are required to keep results stable and comparable over time.

A key premise of the program is that applicants should already be beyond the exploratory stage. NIH explicitly assumes three things are already in place before a project begins under this PAR: first, a candidate biomarker has already been identified; second, a detection method or technology for measuring that biomarker has already been developed; and third, there is an articulated research and/or clinical need for the biomarker along with a plausible "context of use" (meaning a defined way the biomarker is intended to be used, such as monitoring disease progression, stratifying patients, predicting response, or serving as a pharmacodynamic readout). The work supported here is meant to harden the assay and its measurement claims so that subsequent clinical studies are not undermined by variability, drift, or uncertain assay behavior.

Mechanistically, the award uses a U44 cooperative agreement, which is an NIH small business mechanism typically associated with the Small Business Innovation Research (SBIR) program and is structured to support later-stage translational development. A cooperative agreement also generally implies more substantial NIH programmatic involvement than a standard grant, meaning recipients should be prepared for active coordination, milestones, and stewardship consistent with product-focused development. The "clinical trial optional" label means a clinical trial is not required, but the mechanism allows a clinical trial component if it is scientifically justified and fits the scope, such as prospective sample collection or a study designed to assess assay performance in a clinical setting. Even when clinical activities are included, the heart of the project remains analytical validation of the measurement method rather than broad hypothesis-driven clinical discovery.

Eligibility is limited to small businesses, reinforcing the translational and development-oriented intent of the program. Foreign institutions and other non-U.S. entities are not eligible to apply, and non-domestic components of U.S. organizations are also not eligible. However, foreign components as defined under the NIH Grants Policy Statement may be allowed, which typically means a U.S.-based applicant organization can sometimes include a foreign subcomponent if it is well-justified and meets NIH policy requirements, though the applicant itself must remain an eligible U.S. small business. The opportunity is categorized as discretionary funding, uses the Health funding activity category, and is associated with CFDA number 93.853. The issuing agency is NIH. The original closing date listed for the opportunity is 2023-08-07, and the posting indicates it was created on 2020-11-19. The source text does not specify an award ceiling or the expected number of awards, suggesting applicants would need to consult the full funding announcement or NIH SBIR budget guidance for allowable budget levels and project structure expectations.

Overall, this PAR is best understood as a bridge between promising biomarker concepts and the kind of assay-level evidence needed for credible downstream use. It is aimed at teams that already have a biomarker and an assay in hand, and now need to demonstrate, with FDA-aligned rigor, that the measurement is dependable enough to support decision-making in neurological or neuromuscular disease research and development.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853.
• This funding opportunity was created on 2020-11-19.
• Applicants must submit their applications by 2023-08-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for PAR 21 057

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: